Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIDART II: Oral vs IV Iron in IBD-associated Anemia
NCT04587141Phase 3Unknown
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sucrosomial iron in iron deficiency anemia (IDA) (3 arms), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Percentage of patients responsive to iron supplementation at 8 weeks. Status: unknown.
02
Drugs
sucrosomial iron
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT04587141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587141.